From the Department of Experimental Neurology, Center for Stroke Research (P.B.S., S.M.), Department of Radiology (A.H., R.H., E.A.S.), and Charité Core Facility 7T Experimental MRIs (P.B.S., S.M.), Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; and Department of Diagnostic and Interventional Radiology, University of Aachen, Aachen, Germany (C.K.K.).
Radiology. 2018 Feb;286(2):537-546. doi: 10.1148/radiol.2017170116. Epub 2017 Sep 7.
Purpose To synthesize two low-molecular-weight iron chelates and compare their T1 contrast effects with those of a commercial gadolinium-based contrast agent for their applicability in dynamic contrast material-enhanced (DCE) magnetic resonance (MR) imaging. Materials and Methods The animal experiments were approved by the local ethics committee. Two previously described iron (Fe) chelates of pentetic acid (Fe-DTPA) and of trans-cyclohexane diamine tetraacetic acid (Fe-tCDTA) were synthesized with stability constants several orders of magnitude higher than those of gadolinium-based contrast agents. The T1 contrast effects of the two chelates were compared with those of gadopentetate dimeglumine in blood serum phantoms at 1.5 T, 3 T, and 7 T. For in vivo studies, a human breast cancer cell line (MDA-231) was implanted in five mice per group. The dynamic contrast effects of the chelates were compared by performing DCE MR imaging with intravenous application of Fe-DTPA or Fe-tCDTA on day 1 and DCE MR imaging in the same tumors with gadopentetate dimeglumine on day 2. Quantitative DCE maps were generated with software and were compared by means of a one-tailed Pearson correlation test. Results Relaxivities in serum (0.94 T at room temperature) of Fe-tCDTA (r1 = 2.2 mmol · sec, r2 = 2.5 mmol · sec) and Fe-DTPA (r1 = 0.9 mmol · sec, r2 = 0.9 mmol · sec) were approximately twofold and fivefold lower, respectively, compared with those of gadopentetate dimeglumine (r1 = 4.1 mmol · sec, r2 = 4.8 mmol · sec). Used at moderately higher concentrations, however, iron chelates generated similar contrast effects at T1-weighted MR imaging in vitro in serum, in vivo in blood, and for DCE MR imaging of breast cancer xenografts. The volume transfer constant values for Fe-DTPA and Fe-tCDTA in the same tumors correlated well with those observed for gadopentetate dimeglumine (Fe-tCDTA Pearson R, 0.99; P = .0003; Fe-DTPA Pearson R, 0.97; P = .003). Conclusion Iron-based contrast agents are promising as alternatives for contrast enhancement at T1-weighted MR imaging and have the potential to contribute to the safety of MR imaging. RSNA, 2017 Online supplemental material is available for this article.
目的 合成两种低分子量铁螯合物,并将其 T1 对比效果与一种商业的基于钆的对比剂进行比较,以评估其在动态对比增强(DCE)磁共振(MR)成像中的适用性。
材料与方法 动物实验得到了当地伦理委员会的批准。我们用戊二酸(Fe-DTPA)和反式环已烷二胺四乙酸(Fe-tCDTA)两种先前描述过的铁螯合物合成了两种铁螯合物,其稳定常数比基于钆的对比剂高几个数量级。在 1.5T、3T 和 7T 的血清模拟物中,比较了两种螯合物与钆喷酸二甲葡胺的 T1 对比效果。在体内研究中,每组 5 只小鼠植入人乳腺癌细胞系(MDA-231)。通过静脉注射 Fe-DTPA 或 Fe-tCDTA 进行 DCE-MR 成像,并于第 2 天在同一肿瘤中用钆喷酸二甲葡胺进行 DCE-MR 成像,比较两种螯合物的动态对比效果。用软件生成定量 DCE 图,并通过单尾 Pearson 相关检验进行比较。
结果 Fe-tCDTA(r1=2.2mmol·sec,r2=2.5mmol·sec)和 Fe-DTPA(r1=0.9mmol·sec,r2=0.9mmol·sec)在血清中的弛豫率(室温下为 0.94T)分别约为基于钆的对比剂的两倍和五倍(r1=4.1mmol·sec,r2=4.8mmol·sec)。然而,在稍高的浓度下使用时,铁螯合物在体外血清 T1 加权 MR 成像、体内血液以及乳腺癌异种移植的 DCE-MR 成像中产生了相似的对比效果。在同一肿瘤中,Fe-DTPA 和 Fe-tCDTA 的容量转移常数值与钆喷酸二甲葡胺观察到的容量转移常数值相关性良好(Fe-tCDTA Pearson R,0.99;P=0.0003;Fe-DTPA Pearson R,0.97;P=0.003)。
结论 铁基对比剂作为 T1 加权磁共振成像增强的替代物具有很大的潜力,有望提高磁共振成像的安全性。
RSNA,2017 在线补充材料可在本文中获得。